Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.

Chronic respiratory infection by Pseudomonas aeruginosa contributes significantly to the morbidity and mortality associated with cystic fibrosis (CF). Using a series of phenotypic and genotypic tests on collections of 40 isolates per sputum sample, we analysed fluctuations within sputum populations of the P. aeruginosa Liverpool epidemic strain (LES) during pulmonary exacerbations. For each of three patients, three sequential sputum samples were analysed: (1) on presentation with exacerbation at the Regional Adult Cystic Fibrosis Unit, Liverpool; (2) a few days into intravenous antibiotic treatment; (3) when the patient had recovered. Fluctuations were observed in morphotype distribution, the production of virulence-associated quorum-sensing-dependent exoproducts (the phenazine compound pyocyanin and the elastase LasA), antibiotic susceptibility profiles and levels of auxotrophy. PCR assays were used to screen isolates for the presence of novel regions of the LES genome (islands and prophages) and to detect free phages. In one patient there was an increase in the prevalence of the LESGI-5 genomic island during the sampling period from 10 to 97.5 % carriage. LES phages 2-4 were detected in either the majority or all sputum samples tested, indicating widespread phage activity during the sampling period. The results of this study are indicative that significant fluctuations occur within P. aeruginosa populations during short periods of pulmonary exacerbation and intravenous antibiotic therapy.

[1]  D. Bilton,et al.  Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. , 2005, The Journal of antimicrobial chemotherapy.

[2]  A. Oliver,et al.  Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. , 2007, Microbiology.

[3]  T. Pitt,et al.  Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain , 2007, BMC Microbiology.

[4]  A. Oliver,et al.  Increased Susceptibility to Colistin in Hypermutable Pseudomonas aeruginosa Strains from Chronic Respiratory Infections , 2007, Antimicrobial Agents and Chemotherapy.

[5]  J. McElnay,et al.  Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection , 2007, Pediatric pulmonology.

[6]  S. Molin,et al.  Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. , 1999, Microbiology.

[7]  C. Nord,et al.  Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. , 2001, The Journal of antimicrobial chemotherapy.

[8]  T. Pitt,et al.  Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. , 2004, Journal of medical microbiology.

[9]  A. Gerçeker,et al.  In vitro Activities of Various Antibiotics, Alone and in Combination with Colistin Methanesulfonate, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients , 2008, Chemotherapy.

[10]  N. Høiby,et al.  Occurrence of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation , 2005, Antimicrobial Agents and Chemotherapy.

[11]  The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections. , 2009, FEMS microbiology letters.

[12]  P. Ježek,et al.  Low-Frequency Transduction of Imipenem Resistance and High-Frequency Transduction of Ceftazidime and Aztreonam Resistance by the Bacteriophage AP-151 Isolated from a Pseudomonas aeruginosa Strain , 2000, Journal of chemotherapy.

[13]  D. Ohman,et al.  A continuous spectrophotometric assay for Pseudomonas aeruginosa LasA protease (staphylolysin) using a two-stage enzymatic reaction. , 2004, Analytical biochemistry.

[14]  W. Warwick,et al.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. , 1990, The American review of respiratory disease.

[15]  T. Nishino,et al.  Cooperation between Alteration of DNA Gyrase Genes and Over‐Expression of MexB and MexX Confers High‐Level Fluoroquinolone Resistance in Pseudomonas aeruginosa Strains Isolated from a Patient Who Received a Liver Transplant Followed by Treatment with Fluoroquinolones , 2005, Microbiology and immunology.

[16]  H. Yoneyama,et al.  High‐Level Fluoroquinolone Resistance in Pseudomonas aeruginosa Due to Interplay of the MexAB‐OprM Efflux Pump and the DNA Gyrase Mutation , 2002, Microbiology and immunology.

[17]  J. Fyfe,et al.  Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. , 1978, The Journal of antimicrobial chemotherapy.

[18]  C. Hart,et al.  Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients , 2004, Thorax.

[19]  Jerome J. Schentag,et al.  Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosa , 2000, Infection Control & Hospital Epidemiology.

[20]  Anjana Ray,et al.  Increased sputum amino acid concentrations and auxotrophy ofPseudomonas aeruginosa in severe cystic fibrosis lung disease , 2000, Thorax.

[21]  M. Maciá,et al.  Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[22]  M. Denton,et al.  Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. , 2007, The Journal of antimicrobial chemotherapy.

[23]  C. Hart,et al.  Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives , 2002, Thorax.

[24]  C. Goss,et al.  Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.

[25]  I. Lasa,et al.  Killing niche competitors by remote-control bacteriophage induction , 2009, Proceedings of the National Academy of Sciences.

[26]  B. Ramsey,et al.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. , 2003, Chest.

[27]  A. Vanderkelen,et al.  Analysis of epidemic Pseudomonas aeruginosa isolates by isoelectric focusing of pyoverdine and RAPD-PCR: modern tools for an integrated anti-nosocomial infection strategy in burn wound centres. , 1997, Burns : journal of the International Society for Burn Injuries.

[28]  Julian Parkhill,et al.  Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. , 2008, Genome research.

[29]  R. Geffers,et al.  A Cystic Fibrosis Epidemic Strain of Pseudomonas aeruginosa Displays Enhanced Virulence and Antimicrobial Resistance , 2005, Journal of bacteriology.

[30]  A. Oliver,et al.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. , 2000, Science.

[31]  C. Hart,et al.  Use of Subtractive Hybridization To Identify a Diagnostic Probe for a Cystic Fibrosis Epidemic Strain of Pseudomonas aeruginosa , 2002, Journal of Clinical Microbiology.

[32]  C. Hart,et al.  Persistent and aggressive bacteria in the lungs of cystic fibrosis children. , 2002, British medical bulletin.

[33]  L. T. McGrath,et al.  Oxidative stress during acute respiratory exacerbations in cystic fibrosis , 1999, Thorax.

[34]  J. Fothergill,et al.  Transmission of Pseudomonas aeruginosa epidemic strain from a patient with cystic fibrosis to a pet cat , 2008, Thorax.

[35]  C. Hart,et al.  Use of suppression subtractive hybridization to examine the accessory genome of the Liverpool cystic fibrosis epidemic strain of Pseudomonas aeruginosa. , 2006, Journal of medical microbiology.

[36]  J. Lipuma.  Microbiological and immunologic considerations with aerosolized drug delivery. , 2001, Chest.

[37]  M. Denton,et al.  Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic , 1996 .

[38]  D. Cabral,et al.  Mucoid Pseudomonas aeruginosa Resists Nonopsonic Phagocytosis by Human Neutrophils and Macrophages , 1987, Pediatric Research.

[39]  J. Andrews.  BSAC standardized disc susceptibility testing method. , 2001, The Journal of antimicrobial chemotherapy.

[40]  David A. D'Argenio,et al.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Blaise R. Boles,et al.  Endogenous oxidative stress produces diversity and adaptability in biofilm communities , 2008, Proceedings of the National Academy of Sciences.

[42]  J. Sarles,et al.  Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage , 2009, Biology Direct.

[43]  T. Tolker-Nielsen,et al.  Effects of Antibiotics on Quorum Sensing in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[44]  J. Andrews.  BSAC WORKING PARTY ON SUSCEPTIBILITY TESTING FT. BSAC STANDARDIZED DISC SUSCEPTIBILITY TESTING METHOD , 2001 .